mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418

Published: Dec. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Language: Английский

Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies DOI Creative Commons
Mario Fragoso-Saavedra, Qiang Liu

Virology, Journal Year: 2025, Volume and Issue: 604, P. 110412 - 110412

Published: Jan. 19, 2025

Language: Английский

Citations

0
The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice DOI Creative Commons
Daeun Jeong,

Jack Yoon,

Baek Kim

et al.

PLoS neglected tropical diseases, Journal Year: 2025, Volume and Issue: 19(4), P. e0012999 - e0012999

Published: April 30, 2025

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne viral pathogen that causes (SFTS) in humans high fatality rate. Currently, there are no approved antivirals or vaccines against SFTSV. The envelope protein of SFTSV, which consists two domains, Gn and Gc, has been investigated as target antigen for the development SFTSV vaccines. Here, we used an mRNA platform to develop effective safe vaccine. Our vaccine candidate harbored equal number mRNAs individually encoding full-length Gc domain. These were produced using 5' cap, SmartCap, by vitro transcription then packaged ionizable lipid nanoparticle platform, called STLNP. Robust expression these antigens was observed when human 293 T cells transfected formulation. When mice immunized our candidate, collected serum displayed strong immunogenicity neutralization activity Thus, showed complete protection lethal dose without any pathological traces infection-mediated tissue damage. promising SFTS clinical development.

Language: Английский

Citations

0
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1418 - 1418

Published: Dec. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Language: Английский

Citations

1